Ultra-small phospholipid nanoparticles in the treatment of combined hyperlipidemia: a randomized placebo-controlled clinical trial Authors: Alexander Archakov, Valery Kukharchuk, Andrey Lisitsa, Elena Ponomarenko, Yulia Romashova, Tatiana Pleshakova, Elena Yarovaya, Vladimir Kutsenko, Maria Guseva, Valery Beregovykh, Olga Ipatova, Marina Zubareva, Elena Tikhonova, Sergei Ivanov, Farid Bedretdinov, Sergey Markin Published: 2024 ABSTRACT Background and purpose:Combined hyperlipidemia is associated with an increased risk of cardiovascular events. This clinical trial investigated phospholipovit (essential phospholipids, Institute of Biomedical Chemistry, Moscow, Russia), an ultra-small phospholipid nanoparticle (micelles), targeted to phospholipids of HDL in lowering non-HDL-cholesterol (non-HDL-C) and triglycerides (TG) levels in patients with combined hyperlipidemia and moderate cardiovascular risk.Experimental approach:A randomized, double-blinded, placebo-controlled phase II trial was conducted on 100 patients. Phospholipovit or placebo was randomly administered orally (500 mg) 2 times a day for 12 weeks. The primary endpoint was the percent change of non-HDL-C from baseline to 12 weeks of exposure.Findings/Results:Treatment with phospholipovit resulted in a mean non-HDL-C reduction of 13.2% versus 4.3% compared with placebo. The absolute decrease in non-HDL-C was -23.2 (-48.7 - 7.0) mg/dL versus -7.3 (-17.0 - 12.0) mg/dL, significantly. The therapeutic target of non-HDL-C less than 130 mg/dL (3.4 mmol) was achieved in 15 of 39 patients (38.5%) in the phospholipovit group versus 2 of 41 patients (4.9%) in the placebo group OR 11.8 (2.4 - 116). Significant reduction in TG, apolipoprotein B, total cholesterol, and very low-density lipoprotein cholesterol levels was also observed. There were no changes in the liver and kidney functions, vital signs, or electrocardiography. There were no serious adverse events.Conclusion and implications:Phospholipovit significantly reduced non-HDL-C, TG, and atherogenic lipoproteins in patients with combined hyperlipidemia and moderate cardiovascular risk. It can be used as an add-on therapy to statins. INTRODUCTION The combined hyperlipidemia (former hyperlipidemia type IIB or familial combined hyperlipidemia) includes patients with mild to moderate hypertriglyceridemia and low high-density lipoproteins (HDL) cholesterol levels. Circulating triglycerides (TG) are carried by TG-rich lipoproteins (TGL), which are consistently associated with atherosclerotic cardiovascular disease (ASCVD) (1) according to epidemiological studies (2), genome-wide analyses (3), and Mendelian randomization studies (4). All TGL particles contain the apolipoprotein B (ApoB) molecule, and to estimate all atherogenic ApoB-containing lipoproteins, a non-HDL-cholesterol (non-HDL-C), as a standard in clinical practice, is now widely used. Also, there is a high positive correlation between the decrease in non-HDLC and TG (5). HDL is an antiatherogenic substance and its primary function is to promote reverse cholesterol transport (RCT). The first step of RCT is cholesterol efflux from macrophages to HDL, the so-called cholesterol efflux capacity (CEC) (6). The animal study showed the inverse correlation between CEC and the size of atherosclerotic lesions (7). In human studies, the CEC was inversely associated with the incidence of ASCVD (8). Recently, to enhance CEC it was performed a new method for generating ultra-small phospholipid (PL) nanoparticles (micelles) from soybean phosphatidylcholine (PC), which had an average size of 30 nm (9). Also, the micelles were investigated in vitro and in vivo studies. The mass-spectrometric analysis showed that the micelles enriched HDL with dilinoleoyl PC (10). In vitro study showed a dose-dependent 8-fold increase of PL in HDL, and a 2-fold increase in CEC, as compared with native ApoB-depleted plasma, when incubated with micelles (11). In vivo study found that the intravenous administration of micelles in the cholesterol-fed rabbit restored lipid profiles protected the vessel wall from developing intimal lipid lesions, and showed a similar decrease in the extent of atherosclerotic lesions, as compared with atorvastatin and fenofibrate (11). For clinical trials, the water-soluble pharmaceutical form of micelles, phospholipovit, was used. Phase I trial showed the safety of oral administration of phospholipovit (1 g for 1 day) in 14 healthy volunteers. Phospholipovit was well tolerated and no serious adverse events (AE) were observed (12). We hypothesized that the phospholipidation of HDL improves the interactions of lipoproteins, which leads to a decrease in atherogenic lipids. So, the present trial aimed to show the safety and efficacy of 1 g oral administration of phospholipovit daily versus placebo for 12 weeks in changing non-HDL-C, TG, and atherogenic lipoproteins in patients with combined hyperlipidemia and moderate cardiovascular (CV) risk (phase II trial). MATERIALS AND METHODS Trial design This study was a randomized, double-blinded, and placebo-controlled phase II clinical trial for evaluating phospholipovit and conducted in 3 clinical sites in Russia including E.I. Chazov National Medical Research Center of Cardiology, Moscow; Nizhny Novgorod Medical Clinic, Nizhny Novgorod; and Medical Center for Diagnostics and Prevention Plus, Yaroslavl. Sample size calculation was presented in the supplementary appendix 1. The randomization sequence was created by an independent biostatistician using computer-generated random numbers. Twenty-five blocks (block size of 4) of opaque sealed envelopes were numbered sequentially from 1 to 100 and opened in numerical order to receive either phospholipovit (n = 50) or placebo (n = 50). Investigators and patients were unaware of their assigned treatment. Phospholipovit or placebo was administered in a dose of 500 mg orally 2 times a day. The composition of the placebo was maltose used as an excipient in phospholipovit. The treatment period was 12 weeks, with a post-treatment follow-up for 4 weeks, and the screening period lasted 1-3 days. Monitoring and stopping rules were related to liver and renal function, platelet count, other parameters of blood count, biochemical blood analysis, blood pressure (systolic and diastolic), and electrocardiography. The threshold limits were prespecified in the protocol. The current study was conducted according to the guidelines of the Declaration of Helsinki (World Medical Association, 1964 and amended by the 64th General Assembly, Fortaleza, Brazil, 2013), and approved by the Ethics Council of the Ministry of Health of Russia (No. 8414 dated of July 10, 2015) and by the Ministry of Health (No. 05F of March 23, 2016). Informed consent was obtained from all subjects involved in the study. Independent statisticians did the statistical analysis and data interpretation. Eligibility Inclusion criteria Patients who were 30-75 years of age; had no history of diseases such as coronary heart disease (CHD), acute myocardial infarction (MI), stroke, transient ischemic attack, peripheral artery disease, or heart failure; were at moderate CV risk and had TG level of 151 - 399 mg/dL (1.7 - 4.5 mmol/L), HDL-C < 39 mg/dL (< 1 mmol/L) for men, and < 46 mg/dL (< 1.2 mmol/L) for women were eligible for enrollment. Patients were screened in the outpatient department of the E.I. Chazov National Medical Research Center of Cardiology (Moscow, Russia) and other clinical sites. Exclusion criteria Exclusion criteria included diseases or metabolic disorders that can increase low-density lipoproteins (LDL) cholesterol, total cholesterol, and TG (secondary dyslipidemia); patients receiving high doses of statins (rosuvastatin > 40 mg and atorvastatin > 80 mg) and any hypotriglyceridemic drugs, such as omega-3, fibrates, and niacin; type 1 diabetes mellitus (DM); patients with kidney decompensation defined as increase in serum creatinine > 0.3 mg/dL (26.5 pmol/L) within 48 h or > 50% from baseline value known or presumed to have occurred within the prior 7 days and/or urine output < 0.5 mL/Kg for > 6 h; patients with liver decompensation defined by acute development of one or more major complications of liver disease (i.e., ascites, hepatic encephalopathy, gastrointestinal hemorrhage, and bacterial infection), and can be further complicated by organ failures and high short-term mortality; porphyria, myopathy, diseases of the central nervous system, with exacerbation of chronic infections diseases, with acute conditions (infection, injuries, and operations) less than 2 months before screening; patients of a positive human immunodeficiency virus test and positive hepatitis B, C, and syphilis test results; oncology during the last 5 years, hypothyroidism, or thyroid-stimulating hormone levels (TSH) exceeding > 1 upper limit of normal (ULN) during screening; glomerular filtration rate less than 30 mL/min/1.73 m2; alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level exceeding twice the ULN lower than the lower limits of normal range in blood and urine tests; alcohol abuse more than 5 units/week (Table S1). Table S1Inclusion and exclusion criteria.Inclusion criteriaMen and women aged 30-75 years Availability of signed and dated informed consent of the patient to participate in the study Patients with moderate combined hyperlipidemia, defined as: TG 151 - 399 mg/dL (1.7 - 4.5 mmol/L) HDL-C < 39 mg/dL (< 1 mmol/L) for men and < 46 mg/dL (< 1.2 mmol/L) for women Patient consent to use reliable contraceptive methods throughout the study The patient's ability to adequately cooperateDiseases or metabolic disorders that can cause an increase in LDL-C, total cholesterol, and TG (secondary dyslipidemia) Patients receiving high doses of statin drugs (rosuvastatin > 40 mg and atorvastatin > 80 mg) and any hypotriglyceridemic drugs such as omega-3, fibrates, and niacin Type 1 diabetes mellitusAcute kidney injury, defined as an increase in serum creatinine > 0.3 mg/dL (26.5 μmol/L) within 48 h or ≥ 50% from baseline value known or presumed to have occurred within the prior 7 days and/or urine output ≤ 0.5 mL/Kg for ≥ 6 h according to the acute disease quality initiativeLiver decompensation, defined by the acute development of one or more major complications of liver disease (i.e., ascites, hepatic encephalopathy, gastrointestinal hemorrhage, and bacterial infection), and can be further complicated by organ failures and high short-termSevere dysfunction of other vital organs, accompanied by decompensation of their functions; diseases of the central nervous system, with severe impairment of cognitive functionsExclusion criteriaOncological disease during the last 5 years Diagnosed porphyria Diagnosed myopathy Acute conditions (infections, injuries, and operations) in the period less than 2 months before the start of the study Glomerular filtration rate less than 30 mL/min/1.73 m2Persistent increase in liver enzymes activity (AST and ALT) of unclear etiology or increased liver enzymes activity by 2 or more times from the upper limit of the normAlcohol abuse more than 5 units of alcohol for week (1 unit alcohol is equivalent to 0.325 L beer, 130 mL wine, and 30 mL alcohol) Drug use Positive HIV test result Hepatitis B and C, syphilis Any other diseases or conditions that, in the opinion of the investigator, may distort the results of the study and limit the patient's participation in the study.ALT, Alanine aminotransferase; AST aspartate aminotransferase; HDL-C, high-density lipoproteins-cholesterol; HIV, human immunodeficiency viruses; LDL, low-density lipoproteins. Inclusion and exclusion criteria. ALT, Alanine aminotransferase; AST aspartate aminotransferase; HDL-C, high-density lipoproteins-cholesterol; HIV, human immunodeficiency viruses; LDL, low-density lipoproteins. Laboratory measurements All laboratory parameters including total cholesterol, HDL-C, ApoB, ApoA, lipoprotein (a) Lp(a), high-sensitivity C-reactive protein (hs-CRp), AST, ALT, creatinine, complete blood count were measured by commercially available kits (Vital Diagnostics, St. Petersburg, Russia and Erba Lachema s.r.o., Brno, Czech Republic). Non-HDL cholesterol was calculated as follows: total cholesterol minus HDL-C. Low-density lipoproteins cholesterol (LDL-C) was calculated according to the Friedewald formula (13). Very LDL-C (VLDL-C) in mmol/L was calculated as TG level divided by 2.2. Endpoints The primary efficacy endpoint was the percentage change in non-HDL-C from baseline to the time point of 12 weeks of treatment with phospholipovit, as compared with placebo. The secondary efficacy endpoints were the percentage change from baseline in TG, total chol esterol, HDL-C, LDL-C, VLDL-C, ApoB, ApoA, Lp(a), and hs-CRP levels. All endpoints were listed in Table S2. Table S2Efficacy endpoints.The primary efficacy endpointPercentage change from baseline in non-HDL-C values on week 12Dynamics of change of TG level compared with the baseline on week 12 Dynamics of change of total cholesterol level compared with the baseline on week 12 Dynamics of change of HDL-C level compared with the baseline on week 12 Dynamics of change of LDL-C level compared with the baseline on week 12Secondary efficacy endpointDynamics of change of VLDL-C level compared with the baseline on week 12 Dynamics of change of ApoB level compared with the baseline on week 12 Dynamics of change of ApoA level compared with the baseline on week 12 Dynamics of change of Lp (a) level compared with the baseline on week 12 Dynamics of average hs-CRP level compared with the baseline on week 12HDL-C, High-density lipoproteins-cholesterol; LDL-C, low-density lipoproteins-cholesterol; VLDL-C, very-low-density lipoproteins-cholesterol; Lp (a), lipoproteins (a); hs-CRP, high-sensitivity C-reactive protein. Efficacy endpoints. HDL-C, High-density lipoproteins-cholesterol; LDL-C, low-density lipoproteins-cholesterol; VLDL-C, very-low-density lipoproteins-cholesterol; Lp (a), lipoproteins (a); hs-CRP, high-sensitivity C-reactive protein. Statistical analysis Statistical analyses were performed using R statistical software version 4.1 (R Core Team, Vienna, Austria). Continuous variables were presented as mean ± standard deviation (SD) or as the median and interquartile range (median (Q1 - Q3)). Categorical variables were presented as n (%). In the unpaired case, the Mann-Whitney U test was used to compare the distributions of continuous variables, and the two-sided Fisher’s exact test was used to compare categorical variables. In the paired case, the Wilcoxon test was used to compare the distributions of continuous variables, and McNemar’s exact test was used to compare categorical variables. The confidence interval for the median was calculated using the MedianCI function from DescTools R-package version 0.99.46 (Zurich, Switzerland). The odds ratio (OR) was calculated using the Fisher test function from the R-package based on the conditional maximum likelihood estimate, which depends on the sample sizes (14). P-values < 0.05 were considered statistically significant. RESULTS Patients In total, 325 patients were screened, of whom 100 were randomized to receive either phospholipovit or a placebo. One hundred seventy patients had no inclusion criteria; the most common of them were TG level less than 150 mg/dL (1.7 mmol/L) and HDL-C more than 39 mg/dL (1.0 mmol/L) for men and 46 mg/dL (1.2 mmol/L) for women. Fifty-five patients were excluded, most receiving high doses of statins and type 1 DM. The first patient was enrolled in April 2016 and the last in November 2017. Three patients in the phospholipovit group and 2 patients in the placebo group discontinued the trial on the 4th visit. Eight patients in the phospholipovit group and 7 patients in the placebo group were excluded because of non-compliance to the recommended diet (5 versus 4) and enhanced alcohol consumption (3 versus 3). These 20 patients were excluded from the efficacy analysis but were included in the safety analysis (Fig. 1). Trial flow diagram. Phospholipovit or placebo (maltose) was administered orally at 500 mg, 2 times /day for 12 weeks. All included patients had a diet that modified plasma TG and HDL-C levels, according to Russian Atherosclerosis Society Guidelines (15); some of the patients used statins (rosuvastatin in a dose of < 40 mg and atorvastatin in a dose of < 80 mg) for the treatment. The average compliance (percent of the total scheduled volume of drug received) was 78% in the phosholipovit group and 82% in the placebo group. Demographics and baseline characteristics of patients were similar in both groups (Table 1). In the phospholipovit group, at baseline, the mean non-HDL-cholesterol level was 177.4 ± 32.6 mg/dL (4.6 ± 0.8 mmol/L), and the median level was 170.9 mg/dL (156.3 - 206.4) or 4.4 mmol/L (4.0 - 5.3). In the placebo group, at baseline, the mean non-HDL-cholesterol level was 177.0 ± 27.7 mg/dL (4.6 ± 0.7 mmol/L), and the median level was 175.0 mg/dL (155.2 - 199.9) or 4.5 mmol/L (4.0 - 5.2) (Table 1). Table 1Demographic, clinical characteristics at baseline in phospholipovit and placebo groups.Baseline characteristicsPhospholipovit group (n = 50)Placebo group (n = 50)Age (year)55.6 ± 11.157.1 ± 9.2Male sex33 (66)25 (50)White race50 (100)50 (100)BMI (Kg/m2)29.0 (26.1 - 33.0)30.3 (28.1 - 34.0)CV risk factorsDyslipidemia50 (100)50 (100)Hypertension48 (96)49 (98)Ever smoker36 (72)35 (70)Current smoker16 (32)17 (34)Type 2 diabetes1 (2)1 (2)Impaired glucose tolerance6 (12)5 (10)Statins46 (92)47 (94)Platelet aggregation inhibitors48 (96)49 (98)β-adreno-blockers29 (58)31 (62)ACE-inhibitors14 (28)15 (30)Other anti-hypertensive drugs: Ca++antagonists, AT-II inhibitors4 (8)3 (6)Anti-diabetic drugs7 (14)6 (12)Non-HDL cholesterol (mmol/L)4.6 ± 0.84.6 ± 0.7Non-HDL cholesterol (mg/dL)177.4 ± 32.6177.0 ± 27.7Non-HDL cholesterol (mmol/L)4.4 (4.0 - 5.3)4.5 (4.0 - 5.2)Non-HDL cholesterol (mg/dL)170.9 (156.3 - 206.4)175.0 (155.2 - 199.9)Total cholesterol (mmol/L)5.5 (5.0 - 6.3)5.6 (5.0 - 6.2)Total cholesterol (mg/dL)211.5 (192.1 - 243.3)215.2 (195.0 - 241.3)HDL cholesterol (mmol/L)1.0 (0.9 - 1.0)1.0 (0.9-1.1)HDL cholesterol (mg/dL)37.9 (36.0 - 39.0)37.9 (34.8 - 44.5)Triglycerides (mmol/L)2.2 (1.9 - 2.7)2.2 (1.9 - 2.7)Triglycerides (mg/dL)198.0 (169.4 - 239.1)198.8 (169.4 - 238.7)LDL cholesterol (mmol/L)3.3 (2.9 - 4.1)3.3 (2.9 - 3.9)LDL cholesterol (mg/dL)128.4 (111.2 - 157.3)126.5 (111.1 - 149.9)VLDL cholesterol (mmol/L)1.0 (0.9 - 1.2)1.0 (0.9 - 1.2)VLDL cholesterol (mg/dL)39.3 (33.6 - 47.5)39.5 (33.6 - 47.4)Apolipoprotein B (mg/dL)110.5 (98 - 124.8)112.5 (96.8 - 123.8)Apolipoprotein A (mg/dL)132.5 (122.3 - 142.8)137 (128.5 - 149)Lipoprotein (a) (mg/dL)8.5 (3.1 - 33.8)9.6 (5.2 - 16.2)hs-CRP (mg/dL)0.22 (0.14 - 0.4)0.2 (0.11 - 0.43)Phospholipovit or placebo (maltose) was administered orally at the dose of 500 mg, 2 times/day for 12 weeks. Data were expressed as mean ± SD, number (%), or median (Q1-Q3), where applicable. BMI, Body mass index; CV, cardiovascular; ACE, angiotensin-converting enzyme; AT-II, angiotensin-II; HDL, high-density lipoproteins; LDL, low-density lipoproteins; VLDL, very-low-density lipoproteins; hs-CRP, high-sensitivity C-reactive protein. Demographic, clinical characteristics at baseline in phospholipovit and placebo groups. Phospholipovit or placebo (maltose) was administered orally at the dose of 500 mg, 2 times/day for 12 weeks. Data were expressed as mean ± SD, number (%), or median (Q1-Q3), where applicable. BMI, Body mass index; CV, cardiovascular; ACE, angiotensin-converting enzyme; AT-II, angiotensin-II; HDL, high-density lipoproteins; LDL, low-density lipoproteins; VLDL, very-low-density lipoproteins; hs-CRP, high-sensitivity C-reactive protein. Efficacy The primary efficacy endpoint: percent change in non-HDL-C level After 12 weeks of treatment, a statistically significant reduction in non-HDL-C was observed in the phospholipovit group (-13.2% (-29.1% - -3.9%)) compared with the placebo group (-4.3% (-9.9% - 6.5%)) (Table 2). Also, there was a significant difference in the absolute change of non-HDL-C from baseline to 12 weeks between the phospholipovit group (-23.2 mg/dL (-48.7 - -7.0) or -0.6 mmol/L (-1.2 - -0.2)) and the placebo group (-7.3 mg/dL (-17.0 - 12.0) or -0.2 mmol/L (-0.4 - 0.3)) (Table 2). Before treatment, only one patient (in the placebo group) had a level of non-HDL-C less than 130 mg/dL (3.4 mmol/L). After 12 weeks of the treatment, the goal of non-HDL-C < 130 mg/dL (3.4 mmol/L) was achieved in 15 of 39 patients (38.5%) in the phospholipovit group versus 2 of 41 patients (4.9%) in the placebo group (P = 0.001, OR 11.8 (2.4 - 116)). Table 2The primary efficacy endpoint: changes in non-HDL-cholesterol levels in phospholipovit and placebo groups.ParametersPhospholipovit group (n = 39)Placebo group (n = 41)P-value median (Q1 - Q3)95% CImedian (Q1 - Q3)95% CIBaseline non-HDL-C (mmol/L)4.5 (4.1 - 5.3)4.2 - 5.04.7 (4.2 - 5.2)4.3 - 5.00.918Non-HDL-C after 12 weeks (mmol/L)3.8 (3.0 - 4.8)3.1 - 4.44.2 (3.8 - 5.1)3.8 - 4.80.008Absolute change from baseline (mmol/L)-0.6 (-1.2 - -0.2)-1.0 - -0.3-0.2 (-0.4 - 0.3)-0.3 - 0.10.001Baseline non-HDL-C (mg/dL)172.5 (159.3 - 205.3)161.6 - 193.7181.7 (160.9 -201.5)165.1 - 193.00.918Non-HDL-C after 12 weeks (mg/dL)146.6 (117.2 - 183.7)120.7 - 171.7161.3 (146.9 - 198.0)147.7 - 186.40.008Absolute change from baseline (mg/dL)-23.2 (-48.7 - -7.0)-40.6 - -12.8-7.3 (-17.0 - 12.0)-13.1 - 5.00.001% change from baseline-13.2 (-29.1 - -3.9)-23.0 - -5.9-4.3 (-9.9 - 6.5)-8.3 - 3.10.001Phospholipovit or placebo (maltose) was administered orally at the dose of 500 mg, 2 times/day for 12 weeks. Data were expressed as median (Q1 - Q3). HDL, high-density lipoproteins; CI, confidence interval. The primary efficacy endpoint: changes in non-HDL-cholesterol levels in phospholipovit and placebo groups. Phospholipovit or placebo (maltose) was administered orally at the dose of 500 mg, 2 times/day for 12 weeks. Data were expressed as median (Q1 - Q3). HDL, high-density lipoproteins; CI, confidence interval. The secondary efficacy endpoints: changes in lipids and lipoproteins level In this study, 12-week treatment with phospholipovit resulted in a significant reduction in the levels of atherogenic lipids and lipoproteins (Table 3). Table 3The secondary efficacy endpoints: changes in lipids and lipoproteins levels in phospholipovit and placebo groups.ParametersPhospholipovit group (n = 39)Placebo group (n = 41)P-value median (Q1 - Q3)95% CImedian (Q1 - Q3)95% CI Triglycerides Baseline triglycerides, mmol/L2.5 (2.0 - 2.8)2.0 - 2.72.3 (1.9 - 2.7)2.0 - 2.60.382Triglycerides after 12 weeks, mmol/L1.5 (1.3 - 2.3)1.4 - 2.32.2 (1.7 - 2.8)1.9 - 2.60.014Absolute change from baseline, mmol/L-0.7 (-1.2 - -0.3)-1.0 - -0.3-0.1 (-0.5 - 0.4)-0.4 - 0.10.001Baseline triglycerides, mg/dL221.4 (177.6 - 244.9)181.6 - 239.1202.8 (168.3 -175.4 - 230.30.382Triglycerides after 12 weeks, mg/dL136.4 (115.6 - 206.4)119.6 - 201.1194.9 (150.6 -165.6 - 232.10.014Absolute change from baseline, mg/dL-62.0 (-103.6 - -26.6)-90.3 - -28.3-8.9 (-48.7 - 31.9)-35.4 - 10.60.001% change from baseline-23.8 (-48.2 - -12.0)-46.8 - -18.2-3.7 (-20.0 - 15.4)-16.9 - 5.60.000 TC Baseline TC, mmol/L5.5 (5.1 - 6.3)5.2 - 6.15.6 (5.1 - 6.3)5.3 - 6.10.884TC after 12 weeks, mmol/L4.8 (4.1 - 5.9)4.2 - 5.55.6 (4.8 - 6.2)5.0 - 6.10.019Absolute change from baseline, mmol/L-0.6 (-1.0 - 0.1)-0.8 - -0.1-0.1 (-0.4 - 0.3)-0.3 - 0.00.011Baseline TC, mg/dL214.2 (195.5 - 242.3)199.5 - 235.9216.6 (197.6 -205.0 - 237.00.884TC after 12 weeks, mg/dL186.8 (158.7 - 227.2)161.6 - 212.7216.2 (185.6 -193.7 - 235.90.019Absolute change from baseline, mg/dL-23.2 (-38.9 - 3.3)-31.7 - -2.7-5.4 (-15.5 - 10.1)-11.6 - 0.00.011% change from baseline-10.8 (-18.8 - 1.4)-15.6 - -1.4-2.7 (-7.1 - 5.9)-4.3 - 0.00.008 HDL-C Baseline HDL-C, mmol/L1.0 (0.9 - 1.0)1.0 - 1.01.0 (0.9 - 1.2)0.9 - 1.10.779HDL-C after 12 weeks, mmol/L1.1 (1.0 - 1.3)1.0 - 1.21.0 (0.9 - 1.2)1.0 - 1.20.574Absolute change from baseline, mmol/L0.1 (0.0 - 0.2)0.0 - 0.20.0 (0.0 - 0.2)0.0 - 0.10.388Baseline HDL-C, mg/dL37.9 (36.2 - 39.4)37.1 - 38.737.9 (34.8 - 45.6)36.3 - 42.50.779HDL-C after 12 weeks, mg/dL42.5 (37.3 - 49.5)37.5 - 46.439.8 (35.2 - 48.3)37.9 - 46.40.574Absolute change from baseline, mg/dL4.3 (-0.6 - 8.7)0.0 - 7.70.8 (-0.4 - 7.3)0.0 - 3.90.388% change from baseline10.0 (-1.5 - 21.8)0.0 - 18.52.0 (-1.0 - 22.2)0.0 - 10.00.327 LDL-C Baseline LDL-C, mmol/L3.4 (3.0 - 3.9)3.0 - 3.73.5 (2.9 - 3.9)3.1 - 3.90.987LDL-C after 12 weeks, mmol/L3.0 (2.3 - 3.7)2.4 - 3.53.1 (2.8 - 3.8)3.0 - 3.60.206Absolute change from baseline, mmol/L-0.3 (-0.8 - 0.1)-0.7 - 0.0-0.2 (-0.6 - 0.2)-0.5 - 0.10.292Baseline LDL-C, mg/dL130.7 (114.7 - 150.6)117.2 - 141.9135.0 (111.0 -118.3 - 148.90.987LDL-C after 12 weeks, mg/dL116.0 (89.9 - 144.0)94.0 - 135.7121.8 (107.5 -114.1 - 138.80.206Absolute change from baseline, mg/dL-13.1 (-30.9 - 4.4)-28.6 - 0.0-6.4 (-24.2 - 6.2)-18.2 - 2.30.292% change from baseline-11.9 (-23.8 - 3.9)-21.5 - 0.0-5.2 (-19.5 - 6.4)-12.1 - 1.60.234 VLDL-C Baseline VLDL-C, mmol/L1.1 (0.9 - 1.3)0.9 - 1.21.0 (0.9 - 1.2)0.9 - 1.20.382VLDL-C after 12 weeks, mmol/L0.7 (0.6 - 1.1)0.6 - 1.01.0 (0.8 - 1.2)0.8 - 1.20.014Absolute change from baseline, mmol/L-0.3 (-0.5 - -0.1)-0.5 - -0.10.0 (-0.2 - 0.2)-0.2 - 0.10.000Baseline VLDL-C, mg/dL43.9 (35.2 - 48.6)36.0 - 47.540.3 (33.4 - 47.8)34.8 - 45.70.382VLDL-C after 12 weeks, mg/dL27.1 (22.9 - 41.0)23.7 - 39.938.7 (29.9 - 48.3)32.9 - 46.10.014Absolute change from baseline, mg/dL-12.3 (-20.5 - -5.3)-17.9 - -5.6-1.8 (-9.7 - 6.3)-7.0 - 2.10.000% change from baseline-23.8 (-48.2 - -12.0)-46.8 - -18.2-3.7 (-20.0 - 15.4)-16.9 - 5.60.000 Apolipoprotein B Baseline Apolipoprotein B, mg/dL111.0 (98.5 - 124.5)105.0 - 117.0115.0 (99.0 - 125.0)108.0 - 122.00.486Apolipoprotein B after 12 weeks, mg/dL103.0 (88.5 - 125.5)92.0 - 117.0119.0 (105.5 -109.0 - 129.00.011Absolute change from baseline, mg/dL-6.0 (-18.5 - 9.0)-14.0 - 5.02.5 (-5.0 - 13.2)-2.0 - 11.00.015Baseline apolipoprotein B, g/L1.11 (0.98 - 1.25)1.05 - 1.21.15 (0.99 - 1.25)1.08 - 1.20.486Apolipoprotein B after 12 weeks, g/L1.03 (0.88 - 1.25)0.92 - 1.21.19 (1.06 - 1.35)1.09 - 1.30.011Absolute change from baseline, g/L-0.06 (-0.18 - 0.09)-0.14 - 00.03 (-0.05 - 0.13)-0.02 - 0.10.015% change from baseline-5.8 (-18.1 - 8.1)-12.7 - 4.32.3 (-4.1 - 12.2)-1.8 - 8.00.009 Apolipoprotein A Baseline apolipoprotein A, mg/dL134 (122.5 - 143.5)124 - 140137 (124 - 149)131 - 1450.4Apolipoprotein A after 12 weeks, mg/dL139 (120 - 149)128 - 147143.5 (131.5 - 157)135 - 1520.151Absolute change from baseline, mg/dL1 (-10 - 17)-8 - 93 (-4 - 12)-2 - 90.389Baseline apolipoprotein A, g/L1.34 (1.23 - 1.44)1.24 - 1.41.37 (1.24 - 1.49)1.31 - 1.40.4Apolipoprotein A after 12 weeks, g/L1.39 (1.2 - 1.49)1.28 - 1.51.44 (1.31 - 1.57)1.35 - 1.50.151Absolute change from baseline, g/L0.01 (-0.1 - 0.17)-0.08 - 0.10.03 (-0.04 - 0.12)-0.02 - 0.10.389% change from baseline0.9 (-7.3 - 12.9)-5 - 8.22.3 (-2.8 - 9.4)-1.5 - 6.60.422 Lipoprotein (a) Baseline lipoprotein (a), mg/dL11.2 (3.7 - 38.8)5 - 21.98.4 (5.2 - 13.7)5.5 - 12.80.32Lipoprotein (a) after 12 weeks, mg/dL9.1 (3.9 - 22.7)5 - 14.48.8 (5.3 - 12)6.1 - 11.20.596Absolute change from baseline, mg/dL-0.2 (-3.3 - 0.5)-1.5 - 0.3-0.6 (-2.1 - 0.9)-0.8 - 0.50.794% change from baseline-3.5 (-19.6 - 14.3)-11.7 - 8.6-4.6 (-21.1 - 29.3)-12.7 - 14.70.756 hs-CRP Baseline hs-CRP, mg/dL0.21 (0.13 - 0.38)0.15 - 0.30.19 (0.13 - 0.38)0.15 - 0.30.994hs-CRP after 12 weeks, mg/dL0.21 (0.11 - 0.43)0.14 - 0.30.22 (0.12 - 0.38)0.14 - 0.30.746Absolute change from baseline, mg/dL0 (-0.06 - 0.06)-0.05 - 00 (-0.06 - 0.08)-0.05 - 00.91Baseline hs-CRP, mg/L2.1 (1.3 - 3.85)1.5 - 2.71.9 (1.3 - 3.8)1.5 - 30.994hs-CRP after 12 weeks, mg/L2.1 (1.05 - 4.3)1.4 - 3.32.15 (1.2 - 3.83)1.4 - 3.20.746Absolute change from baseline, g/L0 (-0.65 - 0.6)-0.5 - 0.50.05 (-0.62 - 0.8)-0.5 - 0.30.91% change from baseline0 (-40 - 35.9)-26.9 - 21.73.4 (-31 - 45)-14.3 - 26.10.557Phospholipovit or placebo (maltose) was administered orally at the dose of 500 mg, 2 times/day for 12 weeks. Data were expressed as median (Q1 - Q3). CI, Confidence interval; TC, total cholesterol; hs-CRP, high-sensitivity C-reactive protein; HDL-C, high-density lipoproteins-cholesterol; LDL-C, low-density lipoproteins-cholesterol; VLDL-C, very-low-density lipoproteins-cholesterol. The secondary efficacy endpoints: changes in lipids and lipoproteins levels in phospholipovit and placebo groups. Phospholipovit or placebo (maltose) was administered orally at the dose of 500 mg, 2 times/day for 12 weeks. Data were expressed as median (Q1 - Q3). CI, Confidence interval; TC, total cholesterol; hs-CRP, high-sensitivity C-reactive protein; HDL-C, high-density lipoproteins-cholesterol; LDL-C, low-density lipoproteins-cholesterol; VLDL-C, very-low-density lipoproteins-cholesterol. The percentage change of TG between the phospholipovit group (-23.8%) and the placebo group (-3.7%) was significant (Table 3). The percent of patients achieving a fasting TG level < 150 mg/dL (< 1.7 mmol/L) was 56.4% (22 patients) in the phospholipovit group versus 22% (9 patients) in the placebo group (P = 0.003, OR 4.51 (1.58 - 13.8)). There was a significant change in VLDL-C between phospholipovit and placebo groups similar to TG (Fig. 2A). The changes of biochemical parameters including (A) TG, non-HDL-C, TC, ApoB, and VLDL-C and (B) HDL-C, LDL-C, ApoA, Lp (a), and hs-CRP in phospholipovit and placebo groups. Phospholipovit or placebo (maltose) was administered orally at 500 mg, 2 times/day for 12 weeks. Data were presented as median and its confidence intervals. *P < 0.05 indicated a significant difference compared with the placebo group. TG, Triglycerides; TC, total cholesterol; ApoB, apolipoprotein B; VLDL-C, very-low-density lipoproteins-cholesterol; HDL-C, high-density lipoproteinscholesterol; LDL-C, low-density lipoproteins-cholesterol; ApoA, apolipoprotein A; Lp (a), lipoprotein (a); hs-CRP, high-sensitivity C-reactive protein. There was a non-significant tendency in the change of LDL-C between the pho spholipovit (-11.9%) and the placebo (-5.2%) groups. In addition, non-significant change was observed in HDL-C between the phospholipovit (10%) and the placebo (2.0%) groups (Fig. 2B and Table 3). The percentage reduction of total cholesterol was significant between the phospholipovit (-10.8%) and the placebo (-2.7%) groups (Fig. 2A and Table 3). The percentage change of ApoB level showed a significant difference between the phospholipovit (-5.8%) and placebo (2.3%) groups (Fig. 2A and Table 3). There were no significant changes in ApoA, Lp(a), and hs-CRP levels between phospholipovit and placebo groups (Fig. 2B and Table 3). Safety analyses There were no serious AE in both groups. The analysis of serious AE was based on good clinical practice rules, which included events that resulted in death, were life-threatening (an event in which the patient was at risk of death at the time of the event), required inpatient hospitalization, and resulted in persistent or significant disability or incapacity. AE was similar in phospholipovit and placebo groups, 14 (28%) versus 17 (34%), with the majority being mild (93% versus 100%). There was no severe AE in both groups (Table 4). The most frequent AE in phospholipovit versus placebo groups were upper respiratory tract infection (5/14 (12%) versus 5/17 (10%)) and gastrointestinal AE (dyspepsia) (5/14 (10%) versus 4/17 (8%)) (Table 4). Table 4Adverse events and laboratory measurements during 12 weeks of phospholipovit treatment.Parameters, n (%)Phospholipovit group (n=50)Placebo group (n=50)P-valueSerious AE00-Any AE14 (28)17 (34)0.910Mild AE13 (93)17 (100)0.452Moderate AE1 (7)00.452Severe AE00-Upper respiratory tract infection5 (10)5 (10)0.693Dyspepsia5 (10)4 (8)0.477Platelet count < 150,000 mm300-ALT level ≤ 2ULN00-AST level ≤ 2ULN00-Serum creatine increase more 1 mmol/L00-CKD-EPI > 10% decrease from baseline00-Phospholipovit or placebo (maltose) was administered orally at the dose of 500 mg, 2 times/day for 12 weeks. Data were expressed as a number (%). AE, Adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ULN, upper limit of normal; CKD, chronic kidney disease; EPI, epidemiology collaboration formula. Adverse events and laboratory measurements during 12 weeks of phospholipovit treatment. Phospholipovit or placebo (maltose) was administered orally at the dose of 500 mg, 2 times/day for 12 weeks. Data were expressed as a number (%). AE, Adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ULN, upper limit of normal; CKD, chronic kidney disease; EPI, epidemiology collaboration formula. No one patient showed platelet count less than 150.000 mm3 and in other blood cell count in general blood test, which was performed every 4 weeks. No differences were observed in liver biochemical tests, renal function, or significant changes in other laboratory measures, such as glucose. Also, no changes were found in vital signs and electrocardiographic measurements (Table 4). DISCUSSION This study demonstrated that phospholipovit (ultra-small phospholipid nanoparticles-micelles) resulted in a significant decrease in percentage change from baseline of non-HDLC and TG after 12 weeks of treatment with 1 g daily in patients with combined hyperlipidemia at moderate CV risk. According to the PubMed database and https://clinicaltrials.gov/, it was the first randomized placebo-controlled clinical trial, which evaluated the effects of micelles in modifying non-HDL-C and TG levels. The reduction of non-HDL-C after 12-week treatment in the phospholipovit group was 2 times higher, as compared with this parameter in a total of 24 non-statin (fibrates, niacin, and omega 3) trials. In 49 nonstatin and statin trials, the mean reduction of non-HDL-C was -24 mg/dL (-0.6 mmol/L) (5). This finding was similar to the mean reduction of non-HDL-C in the phospholipovit group (-28.3 mg/dL or -0.73 mmol/L). The reduction of TG after 12 weeks of treatment in the phospholipovit group was 2 times higher than that in other 24 non-statin trials, including the biggest one, REDUCE-IT trial, and 3 times higher than that in 25 statin trials (16). In total, the mean reduction of TG in 49 non-statin and statin trials was -25 mg/dL (-0.3 mmol/L) (5), which was comparable with -62.0 mg/dL (-0.7 mmol/L) in the phospholipovit group. The risk ratio of lowering TG and the risk of major vascular events in 49 non-statin and statin trials was 0.84 per 1 mmol/L (P = 0.0026). In contrast, a STRENGTH study performed on the effects of omega-3-fatty acids eicosapentaenoic acid and docosahexaenoic acid showed that the 19% reduction of TG level in statin-treated patients was not associated with reduction in the primary endpoint of significant CV events. Therefore, the STRENGTH study was stopped (17). Recently, a reduction in TG levels (-184 mg/dL or -2.08 mmol/L) was observed in the olerzasen (inhibitor of ApoC-III) phase II study after 6-12 months of treatment (18). Despite the established TG-lowering strategies, therapies that alter the function of HDL particles and reduce the risk of ASCVD, are unknown (19). Strategies for increasing HDL-C through the reconstituted HDL nanoparticles were performed, but most of them were stopped because of serious AE and low efficacy (20212223). Only one trial included more than 18,000 patients was completed in 2024, but its results have not yet been published. (24). Nevertheless, Day’s study reported that only one agent, lecithin as PC, had demonstrated the ability to reverse experimental atherosclerosis (25). In vitro studies showed that super-phospholipidation by PC may increase the CEC (26). The authors speculated that the increase of PL in HDL can promote the enhancement of CEC in patients with metabolic syndrome and early stages of CHD. It was found that these patients had a low CEC, which was associated with low HDL-C and high TG. The small amount of PL in HDL positively correlated with low CEC (r = 0.62, P < 0.001) (27). Recently, a PL nanoparticle, named miNano, was developed (15 ± 1 nm), which directly binds to cholesterol crystals, dissolves them, and enhances CEC. According to experimental data, miNano prevented foam cell formation and stabilized the formation of atherosclerotic plagues. The authors speculated that these findings can provide a novel approach for atherosclerosis treatment by phospholipid nanoparticles miNano (28). These findings were correlated with the results of many different classes of PL and their action in HDL in stable ischemic heart disease (IHD) patients and with acute coronary syndrome (ACS). In patients with ACS, the PC/phosphatidylethanolamine ratio in HDL was less than in stable IHD patients. The authors speculated that the phospholipidation by PC in ACS patients could stabilize the atherosclerotic plaques and prevent them from disruption, leading to future thrombosis and myocardial infarction (29). The phospholipovit phase II trial had some advantages. Micelles were produced without detergents and apoproteins, using only the ultrasonic homogenizer. We made a water-soluble pharmaceutical form of phospholipovit, which was safe and effective for 12-week treatment via oral administration and will be convenient for long-term usage. The phospholipovit phase II trial was not without limitations. The trial was not powered for clinical outcomes as the primary efficacy endpoints. In this study, patients with the clinical features of CV diseases were not included, but only those with risk factors within the age limit of 30 - 75 years. The duration of the treatment was short-term and lasted for 12 weeks. So, the authors suggest that future trials associated with phospholipovit are performed during long-term periods, including patients with combined hyperlipidemia, and the primary endpoint will be the composite of ASCVD events. In summary, we developed water-soluble micelles for oral administration to decrease non-HDL-C and TG in combined hyperlipidemia patients and moderate CV risk. Phospholipovit with daily administration of 1 g for 12 weeks was shown to be safe, well tolerated, and efficacious. CONCLUSION Phospholipovit significantly reduced non-HDL-C, TG, and atherogenic lipoproteins in patients with combined hyperlipidemia and moderated CV risk. Targeting the PL of HDL with phospholipovit is a unique and potent approach for reducing non-HDL-C, TG, and atherogenic lipoproteins. Phospholipovit may have a variety of applications; one of them is the add-on therapy to statin for residual risk reduction of CV events. Conflicts of Interest The authors declared no conflict of interest. Author Contributions A. Archakov contributed to the conceptualization, review, and editing of the manuscript and was a guarantor; A. Lisitsa contributed to the conceptualization, review, and editing; V. Kukharchuk was responsible for the investigation and data curation; E. Ponomarenko, Y. Romashova, and T. Pleshakova were responsible for a project administration and supervision; E. Yarovaya and V. Kutsenko performed statistical analysis; M. Guseva, V. Beregovykh, O. Ipatova, M. Zubareva, and E. Tikhonova were investigators; S. Ivanov and F. Bedretdinov performed the review and editing of the manuscript; S. Markin contributed to the conceptualization, writing, review, and editing of the manuscript. The finalized version was read and approved by all authors. The requirements for authorship as stated earlier in this document have been met. Each author believes that the manuscript represents honest work.